283 related articles for article (PubMed ID: 28925039)
1. Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study.
Nakano Y; Kitago M; Shinoda M; Abe Y; Yagi H; Hibi T; Takeuchi A; Aiura K; Itano O; Kitagawa Y
Cancer Med; 2017 Oct; 6(10):2278-2286. PubMed ID: 28925039
[TBL] [Abstract][Full Text] [Related]
2. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
3. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
[TBL] [Abstract][Full Text] [Related]
4. A lack of postoperative complications after pancreatectomy contributes to the long-term survival of patients with pancreatic cancer.
Kasahara N; Noda H; Kakizawa N; Kato T; Watanabe F; Ichida K; Endo Y; Aizawa H; Rikiyama T
Pancreatology; 2019 Jul; 19(5):686-694. PubMed ID: 31253497
[TBL] [Abstract][Full Text] [Related]
5. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
6. Use of a temporary intraoperative mesentericoportal shunt for pancreatic resection for locally advanced pancreatic cancer with portal vein occlusion and portal hypertension.
Bachellier P; Rosso E; Fuchshuber P; Addeo P; David P; Oussoultzoglou E; Lucescu I
Surgery; 2014 Mar; 155(3):449-56. PubMed ID: 24462078
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
8. Outcome of superior mesenteric-portal vein resection during pancreatectomy for borderline ductal adenocarcinoma: results of a prospective comparative study.
Selvaggi F; Mascetta G; Daskalaki D; dal Molin M; Salvia R; Butturini G; Cellini C; Bassi C
Langenbecks Arch Surg; 2014 Jun; 399(5):659-65. PubMed ID: 24777762
[TBL] [Abstract][Full Text] [Related]
9. International Study Group of Pancreatic Surgery type 3 and 4 venous resections in patients with pancreatic adenocarcinoma:the Paoli-Calmettes Institute experience.
Al Faraï A; Garnier J; Ewald J; Marchese U; Gilabert M; Moureau-Zabotto L; Poizat F; Giovannini M; Delpero JR; Turrini O
Eur J Surg Oncol; 2019 Oct; 45(10):1912-1918. PubMed ID: 31186204
[TBL] [Abstract][Full Text] [Related]
10. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
11. [Surgical therapy of pancreatic cancer - 5 years survival].
Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
[TBL] [Abstract][Full Text] [Related]
12. Portal vein resection in advanced pancreatic adenocarcinoma: is it worth the risk?
Marsoner K; Langeder R; Csengeri D; Sodeck G; Mischinger HJ; Kornprat P
Wien Klin Wochenschr; 2016 Aug; 128(15-16):566-72. PubMed ID: 27363995
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of combined pancreas and portal vein resection in surgery for pancreatic adenocarcinoma.
Aramaki M; Matsumoto T; Etoh T; Ishio T; Himeno Y; Sasaki A; Yada K; Kawano K; Kitano S
Hepatogastroenterology; 2003; 50(49):263-6. PubMed ID: 12630036
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
[TBL] [Abstract][Full Text] [Related]
15. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
16. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvant therapy.
Suto H; Okano K; Oshima M; Ando Y; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Suzuki Y
BMC Surg; 2019 Dec; 19(1):186. PubMed ID: 31796066
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic resection for intraductal papillary mucinous neoplasm- a thirteen-year single center experience.
Marsoner K; Haybaeck J; Csengeri D; Waha JE; Schagerl J; Langeder R; Mischinger HJ; Kornprat P
BMC Cancer; 2016 Nov; 16(1):844. PubMed ID: 27809876
[TBL] [Abstract][Full Text] [Related]
18. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
19. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
Serrano PE; Cleary SP; Dhani N; Kim PT; Greig PD; Leung K; Moulton CA; Gallinger S; Wei AC
Ann Surg Oncol; 2015 Apr; 22(4):1160-7. PubMed ID: 25348784
[TBL] [Abstract][Full Text] [Related]
20. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
